title: Reduced cardiac fructose 2,6 bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction.
abstract: This study was designed to test whether reduced levels of cardiac fructose-2,6-bisphosphate (F-2,6-P(2)) exacerbates cardiac damage in response to pressure overload. F-2,6-P(2) is a positive regulator of the glycolytic enzyme phosphofructokinase. Normal and Mb transgenic mice were subject to transverse aortic constriction (TAC) or sham surgery. Mb transgenic mice have reduced F-2,6-P(2) levels, due to cardiac expression of a transgene for a mutant, kinase deficient form of the enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) which controls the level of F-2,6-P(2). Thirteen weeks following TAC surgery, glycolysis was elevated in FVB, but not in Mb, hearts. Mb hearts were markedly more sensitive to TAC induced damage. Echocardiography revealed lower fractional shortening in Mb-TAC mice as well as larger left ventricular end diastolic and end systolic diameters. Cardiac hypertrophy and pulmonary congestion were more severe in Mb-TAC mice as indicated by the ratios of heart and lung weight to tibia length. Expression of α-MHC RNA was reduced more in Mb-TAC hearts than in FVB-TAC hearts. TAC produced a much greater increase in fibrosis of Mb hearts and this was accompanied by 5-fold more collagen 1 RNA expression in Mb-TAC versus FVB-TAC hearts. Mb-TAC hearts had the lowest phosphocreatine to ATP ratio and the most oxidative stress as indicated by higher cardiac content of 4-hydroxynonenal protein adducts. These results indicate that the heart's capacity to increase F-2,6-P(2) during pressure overload elevates glycolysis which is beneficial for reducing pressure overload induced cardiac hypertrophy, dysfunction and fibrosis.
authors: Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, United States of America.
authors: Jianxun
authors: J
authors: Wang
authors: Jianxiang
authors: J
authors: Xu
authors: Qianwen
authors: Q
authors: Wang
authors: Robert E
authors: RE
authors: Brainard
authors: Lewis J
authors: LJ
authors: Watson
authors: Steven P
authors: SP
authors: Jones
authors: Paul N
authors: PN
authors: Epstein
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001011:Aorta / Q000473:pathology* / Q000601:surgery; D006332:Cardiomegaly / Q000378:metabolism* / Q000503:physiopathology; D003251:Constriction, Pathologic; D005355:Fibrosis / Q000378:metabolism / Q000503:physiopathology; D005635:Fructosediphosphates / Q000378:metabolism*; D006019:Glycolysis; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D018384:Oxidative Stress; D010725:Phosphocreatine / Q000378:metabolism; D025481:Phosphofructokinase-2 / Q000172:deficiency* / Q000235:genetics; D020257:Ventricular Remodeling
chemical_list: D005635:Fructosediphosphates; D010725:Phosphocreatine; C027652:fructose 2,6-diphosphate; D000255:Adenosine Triphosphate; D025481:Phosphofructokinase-2